2011 Fiscal Year Final Research Report
Analysis of the PI3K pathway in colon cancer and new strategy of Molecular target-based drugs.
| Project/Area Number |
21591721
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
SUNAMI Eiji 東京大学, 医学部附属病院, 講師 (70345205)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KITAYAMA Joji 東京大学, 医学部附属病院, 准教授 (20251308)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | 大腸癌 / 化学療法 / mTOR / Rapamycin / 多剤併用療法 |
|---|
| Research Abstract |
We demonstrated that Tesirolimus cause G1 cell cycle arrest in colon cancer cell lines with inhibition of cyclin D1 protein production. Furthermore, we also indicated that Tesirolimus inhibits production of Hypoxia-inducible factor-alpha protein of colon cancer cell lines under the environment of hypoxia. Those explications of the mechanisms of Tesirolimus against cancer proliferation may play an important role in the selection of anticancer agents for colon cancer.
|
